Anti-angiogenic therapy: rationale, challenges and clinical studies.
about
Angiogenesis-inhibitors for metastatic thyroid cancerAnti-angiogenic therapies for metastatic colorectal cancerAnti-angiogenic therapy for metastatic colorectal cancerNoninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGDEndothelial cell pseudopods and angiogenesis of breast cancer tumorsOxidative stress, inflammation, and cancer: how are they linked?Anti-angiogenic effect of tetraacetyl-phytosphingosine.Expression of Angiogenic Factors in Psoriasis VulgarisAngiogenesis inhibitors: current strategies and future prospects.Integrin alpha v beta 3-targeted imaging of lung cancer.Combination therapy of VEGF-trap and gemcitabine results in improved anti-tumor efficacy in a mouse lung cancer modelVascular endothelial growth factor inhibitor-induced hypertension: basics for primary care providers.Live cell integrated surface plasmon resonance biosensing approach to mimic the regulation of angiogenic switch upon anti-cancer drug exposure.CXCR1 and CXCR2 silencing modulates CXCL8-dependent endothelial cell proliferation, migration and capillary-like structure formation.Angiogenesis with biomaterial-based drug- and cell-delivery systems.(99m)Tc-3P-RGD2 molecular imaging targeting integrin α v β 3 in head and neck squamous cancer xenograftMitochondrial dysfunction in cancer.Review article: angiogenesis soluble factors as liver disease markers.Angiogenic inhibitors: a new therapeutic strategy in oncology.Metronomic low-dose chemotherapy as antiangiogenic therapeutic strategy for cancer.Anti-angiogenic therapy: Prospects for treatment of ocular tumors.Mechanisms of adverse effects of anti-VEGF therapy for cancer.Anti-Vascular endothelial growth factor therapy impairs endothelial function of retinal microcirculation in colon cancer patients - an observational studyBevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas.Combining chemotherapy and targeted therapies in metastatic colorectal cancer.Antiangiogenic agents in breast cancer.Anti-VEGF therapy: the search for clinical biomarkers.Vascular endothelial growth factor inhibition by dRK6 causes endothelial apoptosis, fibrosis, and inflammation in the heart via the Akt/eNOS axis in db/db mice.Current available therapies and future directions in the treatment of malignant gliomas.Influence of the tumor microenvironment on angiogenesis.Mechanisms of antiangiogenic-induced arterial hypertension.Beyond bevacizumab: new anti-VEGF strategies in colorectal cancer.Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration: an overview.Photoinduced Isomerization and Hepatoxicities of Semaxanib, Sunitinib and Related 3-Substituted Indolin-2-ones.Effects of the knockdown of hypoxia inducible factor-1α expression by adenovirus-mediated shRNA on angiogenesis and tumor growth in hepatocellular carcinoma cell lines.Kinase domain insert containing receptor promoter controlled suicide gene system selectively kills human umbilical vein endothelial cells.Kinase domain insert containing receptor promotor controlled suicide gene system kills human umbilical vein endothelial cells.Inhibition of tumour angiogenesis and growth by small hairpin HIF-1α and IL-8 in hepatocellular carcinoma.Current concepts in the pathogenesis of psoriasis.Anti-Angiogenic Drugs: Involvement in Cutaneous Side Effects and Wound-Healing Complication.
P2860
Q24236743-B0520BE8-6FF1-4396-9752-0E0051249C14Q24241813-02B5CD99-2DE1-43D2-842D-1C117F958722Q24243297-74D03753-A792-4C8D-B4D9-40C04F57CF40Q24805375-324254C8-AB84-4FE7-B2D5-FA249BF45643Q24811258-2F8B2A01-7C0E-4D9D-85AB-140823D8D7F6Q29616835-CFC8E390-2A40-4150-B851-2646ADFE3A52Q33278565-EB727909-D101-4BB8-BE8F-AD1E129252D6Q33666312-F4AB7610-6BE8-4FC4-A5DC-62E998E053D1Q34056376-0B7BD8C6-206E-45D4-9B23-A2E32D6BE443Q34768362-6CD7302C-CD29-44EF-BFDE-B9F140216B69Q34849516-F764E636-4C30-4278-9375-E97DD307D6BFQ34996468-715C935B-1227-4D74-B945-290D84082912Q35213093-F9E7680B-686B-4BBB-90B8-8971358C641BQ35549511-D9C3E301-B9C8-4983-8A68-2BD10CE759B7Q35837499-C5DC1B1B-E72C-4774-A05B-63021007D944Q35888323-E6A5E542-B806-4FE8-A417-26058D26220CQ35903564-5E5D668E-7323-48E1-B578-D9B0605EC4D0Q36166374-BFD7A5E1-4905-41CD-9019-5D5739968DE1Q36306264-D784F2EC-1333-475C-8488-5F27A6B8803CQ36341538-509EB1CC-B7B0-4EBA-A6DD-82E3BA785FE9Q36567094-9307D1EB-4972-40AA-9B83-916845226094Q36609627-8B547130-9087-4048-ABEB-CB20485933A4Q36858624-9C747168-2BED-4D96-BC9F-EAC85E239862Q36900428-F7E70F3F-EC6A-4F57-87F7-FF7A11D0C68EQ36996324-75987057-61ED-4353-9D0C-F814946C641BQ37008618-57812475-8DD5-4EA3-95FB-66120D1109E8Q37206167-A3F1F0F3-3472-47EA-9200-E37F373952B8Q37400759-07BF994A-41FE-4C92-96F3-520601B055A9Q37586907-E9984F43-0EBC-484A-BC89-85B40FA4CA3CQ37854731-D60E793D-958A-4207-8D67-D1259FE63A4CQ37863585-D0B255DB-872B-497E-ACB7-1519572A087BQ38011768-BDA52D5F-0F43-480E-9E55-E5E02ECCC234Q38210239-5E164467-72DA-47ED-9CCF-4563074BFACBQ38817731-66DE01BB-E28A-46B3-809A-98E15358A551Q39647908-D15E0828-B645-41C2-B74E-5D35D52E3DC5Q40230755-3B776BD7-01BE-4603-8AC0-AE740D831940Q41811991-4165DE24-15EB-41F0-9603-552A1F4FD958Q42250191-71F4717B-C211-46D3-B3DD-FC8F483C32A0Q42283126-9D6C4EA0-1EBF-4BDD-A693-9B59C736322BQ42926957-1EA6F04E-64AA-44FC-825E-C2DEEA38EED2
P2860
Anti-angiogenic therapy: rationale, challenges and clinical studies.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Anti-angiogenic therapy: rationale, challenges and clinical studies.
@ast
Anti-angiogenic therapy: rationale, challenges and clinical studies.
@en
type
label
Anti-angiogenic therapy: rationale, challenges and clinical studies.
@ast
Anti-angiogenic therapy: rationale, challenges and clinical studies.
@en
prefLabel
Anti-angiogenic therapy: rationale, challenges and clinical studies.
@ast
Anti-angiogenic therapy: rationale, challenges and clinical studies.
@en
P2093
P356
P1433
P1476
Anti-angiogenic therapy: rationale, challenges and clinical studies.
@en
P2093
B Capaccetti
G Gasparini
R Sarmiento
P2888
P304
P356
10.1023/A:1024532022166
P577
2002-01-01T00:00:00Z
P6179
1016572371